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Introduction
Progranulin (PGRN) is an evolutionarily conserved Cys-rich 
secreted glycoprotein easily measurable in blood and cere-
bral spinal fluid (Toh et al., 2011). Structurally, progranulin 
encompasses seven and a half repeats of the granulin module 
(arranged in the sequence, P-G-F-B-A-C-D-E) and is charac-
terized by a unique protein architecture comprising a stack of 
β hairpins. Each granulin subdomain contains four β hairpins 
“stapled” together by six parallel disulfide bridges, with 12 
Cys residues per granulin module, culminating in a distinctive 
ladder-shaped topological superstructure (Tolkatchev et al., 
2008; Toh et al., 2011).
The expression of progranulin is ubiquitous and encom-
passes diverse cell types such as rapidly cycling epithelial cells 
(Serrero and Mills, 1991), leukocytes (Toh et al., 2011), mi-
croglial cells (Toh et al., 2011), bone marrow cells (Bhandari 
et al., 1992), and chondrocytes (Xu et al., 2007), as well as 
functioning as a key mitogen found in the secretome of Hobit 
osteoblastic and osteocytic cells (Romanello et al., 2014). The 
pleiotropic biological manifestations of progranulin may, in 
part, stem from its modular architecture, as each granulin can 
be liberated by secreted neutrophil proteases (e.g., elastase, 
matrix metalloproteinase [MMP]-12, MMP-14, proteinase 3), 
with each possessing distinct biological effector functions, 
presumably downstream of their cognate binding partner and/
or receptor. Progranulin has roles beyond development and is 
central for maintaining organismal homeostasis (Bhandari et 
al., 1996; Cenik et al., 2012).
There is mounting evidence that progranulin overexpres-
sion is linked to cancer progression (Monami et al., 2006, 2009; 
Buraschi et al., 2016; Tanimoto et al., 2016), wound healing (He 
et al., 2003), aging (Ahmed et al., 2010), and inflammation (Toh 
et al., 2011), as well as obesity and insulin resistance (Matsubara 
et al., 2012). In contrast, low circulating levels of progranulin, 
resulting from mutations in the progranulin gene (GRN), cause 
frontotemporal dementia (Gijselinck et al., 2008). Moreover, 
the lysosomal storage disorder, neuronal ceroid lipofuscinosis, 
results from GRN homozygous mutations and is clinically rec-
ognized by cerebellar ataxia, progressive vision loss, seizures, 
and retinal dystrophy (Kohlschütter and Schulz, 2009; Smith 
et al., 2012). In both conditions, there is profound loss of cir-
culating progranulin. Further, decreased levels of progranulin 
have been found in children diagnosed with autism (Al-Ayadhi 
and Mostafa, 2011). Progranulin may also play a larger role in 
other neurodegenerative disorders such as amyotrophic lateral 
sclerosis (Sleegers et al., 2008), Alzheimer’s disease (Minami et 
al., 2014), and Parkinson’s disease (Van Kampen et al., 2014).
Despite the fundamental understanding of progranulin 
action and the elucidation of shared core signal transduction 
pathways (MAPK and phosphoinositide 3-kinase [PI3K]/Akt/
FAK; Zanocco-Marani et al., 1999), the signaling receptor is 
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still elusive. Two candidate receptors, sortilin (gene symbol 
SORT1; Hu et al., 2010) and the TNF receptor (TNFR1; Tang 
et al., 2011), have recently emerged as the potential “missing 
links” for progranulin biology. Sortilin is a conventional sin-
gle-pass transmembrane protein and member of the Vps fam-
ily (Vps10) of cell surface, nonsignaling, endocytic receptors 
(Nykjaer and Willnow, 2012). Sortilin is used for extracellular 
progranulin internalization (Hu et al., 2010) that strictly relies 
on proper SORT1 mRNA splicing for the generation of a func-
tional progranulin receptor (Prudencio et al., 2012). Sortilin loss 
might contribute to prostate cancer progression by enhancing 
progranulin action in castration-resistant prostate cancer cells 
(Tanimoto et al., 2015). Recently, we have shown that drebrin, 
an F-actin–binding protein, binds progranulin and is critical for 
progranulin-dependent activation of motility, invasion, and an-
chorage-independent growth of urothelial carcinoma cells (Xu 
et al., 2015). On the other hand, the discovery of TNFR1 as a 
receptor for progranulin has provided tantalizing insights and 
therapeutic promise regarding the mechanism governing the 
anti-inflammatory properties of progranulin (Tang et al., 2011). 
However, both sortilin and TNFR are currently the subject of 
contention, as progranulin can mediate axonal outgrowth inde-
pendently of sortilin (Gass et al., 2012) and TNFR may or may 
not be a direct target (Chen et al., 2013; Wang et al., 2015).
Using the yeast two-hybrid system, we previously dis-
covered that progranulin binds specifically to the C terminus 
of perlecan, termed endorepellin (Gonzalez et al., 2003), and 
mapped the binding to a region encompassing granulins B/A 
(Iozzo, 2005). We found that expression of progranulin and 
perlecan overlapped in a series of ovarian carcinomas (Gon-
zalez et al., 2003), especially within the tumor microvessels. 
Because perlecan is expressed in both vascular and avascular 
compartments (Iozzo, 2005; Zoeller et al., 2008; Farach-Carson 
et al., 2014; Lord et al., 2014a; Wilusz et al., 2014; Iozzo and 
Schaefer, 2015), as well as by various inflammatory cells (Lord 
et al., 2014b), it is likely that proteolytic processing of perle-
can (Whitelock et al., 2008; Grindel et al., 2014) would release 
progranulin into the microenvironment. Moreover, progranulin 
promotes cell growth, migration, and invasion of prostate and 
bladder tumor cells, breast carcinomas, and multiple myelomas 
(He and Bateman, 2003; Monami et al., 2006, 2009; Bateman 
and Bennett, 2009; Lovat et al., 2009), as well as promoting 
angiogenesis (Toh et al., 2013).
Here, we have identified EphA2, a member of a large fam-
ily of receptor tyrosine kinases (RTKs), as a functional signal-
ing receptor for progranulin. Moreover, we provide evidence 
that progranulin regulates its own expression in an EphA2- 
dependent, but sortilin-independent, manner. The discovery 
of a functional progranulin receptor such as EphA2 provides 
avenues of investigation that might lead to a better molecular 
understanding of neurodegenerative diseases and new clues 
about cancer development.
Results
Progranulin activates EphA2
Based on the biological properties of progranulin and down-
stream activation of MAPK and PI3K/AKT pathways, it 
has been postulated that progranulin interacts with a classic 
RTK (Zanocco-Marani et al., 1999; He and Bateman, 2003). 
In addition, chemical cross-linking experiments with either 
progranulin or granulins have identified putative receptors 
ranging between 120 and 140 kD in a variety of cells (Culous-
cou et al., 1993; Xia and Serrero, 1998), consistent with the 
size of RTKs. To identify potential progranulin receptors, we 
used antibody arrays that simultaneously examine differential 
Tyr phosphorylation levels of 49 different human RTKs. We 
have successfully used this strategy to identify Met as a novel 
decorin receptor (Goldoni et al., 2009). Throughout our study, 
we used highly purified (99.7%) human recombinant progranu-
lin free of copurifying contaminants (Fig. S1 A), as determined 
by colloidal Coomassie blue staining, which has a detection 
threshold of as little as 5 ng of protein. Full details regarding 
the purification of progranulin can be found in Materials and 
Methods. Initially, we tested T24 urothelial carcinoma cells, as 
they respond to progranulin (Lovat et al., 2009). After 10-min 
exposure of quiescent (serum-starved) T24 cells to progranulin, 
rapid phosphorylation of three members of the Eph family of 
RTKs, EphA2, EphA4, and EphB2, as well as epidermal growth 
factor receptor (EGFR; Fig. 1 A) was found. Using short expo-
sures, the first receptor to be consistently phosphorylated was 
EphA2. Immunoprecipitation and immunoblotting experiments 
confirmed rapid and sustained activation of EphA2 by progran-
ulin (Fig. 1 B). Similar activation was observed in human um-
bilical vein endothelial cells (HUV ECs; Fig. 1 C), which are to 
express high levels of EphA2, and PC3 cells (Fig. S1 B), which 
also express high levels of EphA2 (Miao et al., 2000). We per-
formed an experiment similar to that in Fig. 1 C, wherein we 
used BSA and EphrinA1-Fc as negative and positive controls, 
respectively. We found EphA2 activation with progranulin and 
EphrinA1-Fc, but no phosphorylation with BSA (Fig. S1 C). 
Because EphrinA1-Fc can stimulate EphA2 (Yang et al., 2011), 
we recapitulated EphA2 phosphorylation in comparison with 
progranulin (Fig. S1 D). Further, we evaluated doxazosin, a pre-
viously characterized EphA2 agonist (Petty et al., 2012), and 
found EphA2 activation in PC3 cells, but to a lesser degree than 
with progranulin (Fig. S1 D).
To ascertain the role of EphA2 in the concurrent activation 
of EGFR, EphA4, and EphB2, we verified depletion of EphA2 
in T24 cells and evaluated the phosphorylation of each receptor 
in the presence of progranulin (Fig. S1 E). To this end, EGFR, 
EphA4, and EphB2 were immunoprecipitated and verified (Fig. 
S1 E), followed by immunoblotting with an anti-phosphoty-
rosine monoclonal antibody (clone 4G10) to detect tyrosine 
phosphorylation. We found that loss of EphA2 prevented pro-
granulin-mediated activation of all three receptors, positing a 
central role for EphA2 in the receptor cross talk as a response to 
progranulin (Fig. S1 E).
Progranulin physically interacts 
with EphA2
To determine physical interaction between progranulin and 
EphA2, we performed solid-phase binding assays in which pro-
granulin served as the immobilized substrate and EphA2-Fc, a 
chimerical protein containing the entire ectodomain of EphA2 
fused to the Fc fragment of IgG, as the soluble ligand, or vice 
versa. EphA2-Fc bound progranulin in a concentration-dependent 
and saturable manner (Kd ∼18 nM; Fig.  2  A); progranulin 
bound EphA2-Fc with similar kinetics (Kd ∼35 nM; Fig. 2 B). 
EphrinA1, the natural ligand of EphA2, bound immobilized 
EphA2-Fc with an affinity comparable to that of progranulin (Kd 
∼17 nM; Fig. 2 C). Next, we used lithocholic acid (LCA), a bile 
salt that acts at the level of Eph–Ephrin interactions by disrupting 
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binding at the ligand/ectodomain interface (Giorgio et al., 2011). 
Increasing concentrations of LCA efficiently displaced progran-
ulin bound to EphA2 (half-maximal inhibitory concentration 
[IC50] = 42 µM; Fig. 2 D). Surprisingly, LCA modestly displaced 
bound EphrinA1-Fc (IC50 = 850 µM; Fig. 2 E). We controlled 
for any potentially compounding effects conveyed by the Fc re-
gion by using a nonrelevant Fc binding protein (VEG FR1-Fc; 
Fig. 2 F, red triangles) and found no significant binding to im-
mobilized EphA2-Fc (red triangles). We also used a similarly 
sized (85-kD) His6-tagged protein known as endorepellin that 
is produced in our laboratory with the same methodologies as 
progranulin and found no significant binding to EphA2-Fc 
(Fig. 2 F, black circles). Collectively, the lack of VEG FR1-Fc and 
endorepellin binding to EphA2-Fc substantially verifies the effi-
cacy and specificity of our binding studies. Complementing the 
solid-phase binding assays, we used microscale thermophoresis 
(Wienken et al., 2010) to confirm binding of fluorescently la-
beled progranulin or EphrinA1 to EphA2-Fc. Progranulin bound 
EphA2 with high affinity (Kd = 1.2 ± 0.3 nM; Fig. 2 G), whereas 
the interaction of EphrinA1 with EphA2 was significantly 
weaker (Kd = 75.2 ± 15.8 nM; Fig. 2 H). As negative controls, no 
binding was detected between EphA2-Fc and BSA (Fig. 2 I) or 
progranulin and BSA (Fig. 2 J).
We further extended the physical interaction of pro-
granulin with EphA2-Fc in solution using pull-down exper-
iments. EphA2-Fc was bound to protein A–Sepharose beads 
(PA-EphA2-Fc) to mimic a more physiologically oriented re-
ceptor surface. Under physiological salt and pH conditions, 
progranulin bound specifically to immobilized PA-EphA2-Fc 
(Fig. S1 F) and not in the absence of PA-EphA2-Fc. Compa-
rable results were obtained in pull-down experiments in which 
equimolar amounts of progranulin and EphA2-Fc were first 
incubated individually and then precipitated with protein A– 
Sepharose beads (Fig. S1 G).
To further investigate progranulin–EphA2 interaction, 
we used affinity chromatography with His6-tagged progranulin 
bound to Ni-NTA beads and PC3 lysates (these cells express 
high levels of EphA2; see Progranulin binds EphA2 at the cell 
surface). After binding in a buffer containing low amounts of 
imidazole, the bound material was eluted using high imidazole. 
Under such conditions, we detected significant binding of en-
dogenous EphA2 to the progranulin affinity column (Fig. S1 H).
To completely eliminate any confounding effects con-
ferred by the fused Fc domain (Fig. 2 F), we used a cell-free 
coupled transcription/translation system to express full-length 
human EphA2 (Fig. S1 I). After incubation with recombinant 
progranulin, we could efficiently coimmunoprecipitate the two 
proteins (Fig. S1 J). Importantly, EphA2 was not detected in the 
immunoprecipitate of a negative IgG control or when EphA2 
was omitted (Fig. S1 J).
Collectively, these reciprocal binding experiments and 
cell-free approaches substantiate a high-affinity, physical inter-
action between EphA2 and progranulin.
Progranulin colocalizes with EphA2
To corroborate the binding studies, we treated HUV ECs with 
recombinant progranulin for various times and used confocal 
laser microscopy. Notably, under basal conditions, endogenous 
progranulin colocalized with EphA2 (Fig. 3, A–E). We imaged 
the field at low magnification for each time point (Fig. 3, A, F, 
and K) and captured high-magnification images from this rep-
resentative view (Fig. 3, B–D, G–I, and L–N). Individual chan-
nels showed a codistribution of EphA2 (Fig. 3, B and C, green) 
and progranulin (red) puncta within cytosolic and membra-
nous compartments. Semiquantitative line scanning confirmed 
significant overlap among the differentially labeled pixels 
(Fig. 3 E). The area measured for line scanning is designated by 
the dotted line between the white arrowheads (Fig. 3, D, I, and 
N). Exogenous progranulin (10 min) promoted intense colocal-
ization with EphA2 (Fig. 3, F–I). Importantly, this relationship 
was clearly depicted within the individual channels (Fig. 3, G 
and H) and reinforced by line scanning (Fig. 3 J). Longer pro-
granulin exposure (20 min) had a less colinear appearance and 
a more punctate morphology (Fig. 3, K–N). Colocalization was 
further confirmed via line scanning (Fig. 3 O). Importantly, we 
detected no signal when omitting the EphA2 primary antibody 
(Fig. 3 P), indicating specificity.
The interaction of progranulin with EphA2 was quanti-
fied by calculating the Pearson coefficient of colocalization per 
individual channel and for the overlapped pixels (Misaki et al., 
2010; Dunn et al., 2011; Zinchuk et al., 2011). As per the basal 
association of progranulin with EphA2, there were already sev-
eral contributing pixels for EphA2 (Fig. 3 Q) and progranulin 
(Fig. 3 R), resulting in a moderate degree of overlap (Fig. 3 S). 
Figure 1. Progranulin activates EphA2. (A) Phospho-RTK ar-
rays of serum-starved T24 cells and T24 cells treated with 
progranulin for 10 min (100 nM). Note that after progranulin 
incubation EGFR, EphA2, EphA4, and EphB2 are phosphor-
ylated. (B) Immunoprecipitation (IP) of EphA2 from quiescent 
T24 cells exposed to progranulin (100 nM) for the times in-
dicated. The immunoprecipitated extracts were probed with 
PY20 and detected by chemiluminescence, stripped, and 
reprobed with anti-EphA2 or anti-Erk1/2.  The Coomassie 
blue–stained markers, as detected by infrared, appear in lane 
1. (C) Immunoprecipitation of EphA2 from HUV ECs followed 
by EphA2 and phospho-Tyr immunoblots (IB; left and right, 
respectively) in the absence or presence of progranulin, as 
denoted by − or + above the lane. Cells were treated with 
progranulin for 30 min.
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However, as exogenous progranulin was added, the proportion 
of individual and overlapped pixels involved in the colocaliza-
tion for EphA2 and progranulin increased significantly (Fig. 3, 
Q–S). Further, a longer treatment time (30 min) had a similar 
proportion of colocalized pixels (Fig.  3, Q–S; unpublished 
data). Colocalization of progranulin and EphA2 was done by 
focusing on entire cells. The representative images and quanti-
fications were not done solely for a particular cellular compart-
ment, but rather for all colocalized pixels present. The provided 
images are representative of this method.
Because we did not observe robust staining of progranu-
lin and EphA2 at the plasma membrane, we hypothesized that 
Figure 2. Progranulin interacts with EphA2. (A and B) Solid-phase binding assays using progranulin (100 ng/well) as immobilized substrate and 
EphA2-Fc as soluble ligand (A) or EphA2-Fc (100 ng/well) as immobilized substrate with soluble progranulin (B). (C) Solid-phase binding assay using im-
mobilized EphA2-Fc and EphrinA1-Fc as a soluble ligand. (D and E) Displacement of bound progranulin (100 ng/well; D) or bound EphrinA1-Fc (100 ng/
well; E) from EphA2-Fc with LCA. (F) Solid-phase binding assay using immobilized EphA2-Fc (100 ng/well) and a nonrelevant Fc-fusion protein, VEG FR1-Fc 
(red triangles) or endorepellin (black circles). (G) Interaction between fluorescently labeled, purified progranulin (20 nM) with recombinant EphA2-Fc. 
(H) Interaction of fluorescently labeled EphrinA1-Fc (20 nM) with recombinant EphA2-Fc. Changes in thermophoresis at concentrations (of EphA2-Fc) from 
1 µM to 0.4 nM were used. (I and J) BSA served as a negative control for binding EphA2-Fc (I) and progranulin (J). Labeled progranulin (20 nM) with 
increasing concentrations of nonlabeled BSA (up to 10 µM) were used, and changes in thermophoresis were measured. The reported Kd was calculated 
from four independent thermophoresis measurements. FNorm (%) indicates normalized fluorescence per million. Values represent the mean ± SEM of three 
independent experiments performed in triplicate.
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lack of colocalization at the cell surface may be caused by rapid 
uptake and internalization of progranulin. Therefore, we eval-
uated very short time points (1, 4, and 8 min) and found that 
at 1 min, we could see colocalization at the plasma membrane 
(Fig. S2 A, white arrows). However, at subsequent time points 
(4 and 8 min), progranulin was rapidly internalized together 
with EphA2 (Fig. S2 A).
Parallel results were obtained in PC3 cells stimulated 
with progranulin (Fig. S2 B). Similarly, progranulin elicited 
rapid, robust, and transient activation and clustering of EphA2 
as measured by receptor phosphorylation in as little as 5 min 
(Fig. S2 C, white arrows). A hallmark of EphrinA1 activity is 
EphA2 internalization (2 h; Wykosky et al., 2008); therefore, 
we evaluated the same effect of progranulin on EphA2 in HUV 
ECs. We found that progranulin internalizes EphA2 over time 
(Fig. S2 D) in a manner similar to EphrinA1-Fc (Fig. S2 C). 
Because EphA2 has a propensity to form receptor-rich clusters, 
we tested whether EphA2 can interact with the aforementioned 
progranulin receptors, TNFR1 or sortilin. We found that there 
is no interaction of EphA2 with either TNFR1 or sortilin in 
the absence or presence of progranulin in HUV ECs (Fig. S2 
E) or PC3 cells (Fig. S2 F). Collectively, these data further 
authenticate the results obtained with a visual and biochemi-
cal depiction of the tight and exclusive interaction involving 
only progranulin and EphA2.
Progranulin binds EphA2 at the 
cell surface
Next, we investigated whether progranulin would bind to the 
surface of PC3 cells. Using soluble progranulin conjugated 
with the near-infrared dye IR800 (Fig. 4 A), we found satura-
ble binding to immobilized EphA2-Fc (Kd ∼50 nM, Fig. 4 B). 
Specificity was determined via in-cell binding assays in which 
IR800-progranulin was incubated with confluent PC3 cells for 
15 min, followed by incubation with increasing concentra-
tions of unlabeled EphrinA1-Fc. IR800-progranulin could be 
Figure 3. Progranulin colocalizes with EphA2. (A–E) Representative confocal images of vehicle-treated cells evaluated at low magnification (A) for EphA2 
(B), progranulin (C), and both (D) at high magnification from the same field as in A. (E) Line scanning profiles for colocalized pixels shown in D and 
measured between the white arrows, indicated by the dotted line. Exogenous progranulin for 10 min (F–J) and associated line scan analysis (J) and for 20 
min (K–O) with line scanning (O). (P) EphA2 primary antibody was omitted as a negative control. All images were taken with the same exposure, gain, 
and intensity. Bar, ∼10 µm. (Q–S) Pearson’s coefficient of colocalization was calculated for EphA2 (Q), progranulin (R), and the degree of overlap (S) for 
each time point. Values represent the mean of three independent experiments in HUV ECs and are represented as box plots. Statistics were generated by 
one-way ANO VA (***, P < 0.001).
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displaced by EphrinA1-Fc (Fig. 4 C) with an IC50 of ∼400 nM 
(Fig. 4 D). Using the same approach for LCA, IR800-progran-
ulin was significantly displaced (Fig. 4, E and F), suggesting 
impaired binding of progranulin to EphA2 at the cell surface 
in the presence of LCA. It is important to note that LCA, at the 
doses used (50 or 100 µM), does not perturb the activity of other 
RTKs (Giorgio et al., 2011).
The role of EphA2 as a putative high-affinity receptor for 
progranulin was further substantiated by depleting the receptor and 
evaluating progranulin binding at the cell surface. After authenti-
cating EphA2 silencing (Fig. 4 G), we added IR800-progranulin 
and determined cell surface binding of the labeled ligand. In a 
manner that parallels pharmacological inhibition, overt loss of 
EphA2 substantially prevented cell surface binding of progranu-
lin (Fig. 4, H and I). Thus, we provide three distinct and comple-
mentary methodologies that collectively establish EphA2 as an 
authentic cell surface receptor for progranulin.
Progranulin activation of MAPK and Akt is 
EphA2 dependent
Because progranulin activates canonical MAPK and Akt sig-
naling, presumably downstream of an RTK (Zanocco-Marani et 
al., 1999), we tested the phosphorylation of MAPK and Akt in 
PC3 cells and HUV ECs in response to progranulin over time. A 
Figure 4. Progranulin binding requires 
EphA2 at the cell surface and stimulates MAPK 
and Akt. (A) Gel of increasing concentrations 
of IR800-labeled progranulin (B) solid-phase 
binding assay of labeled progranulin to im-
mobilized EphA2-Fc. (C) In-cell binding using 
equimolar equivalencies of either IR800-pro-
granulin (C, top) or IR800-progranulin in 
combination with EphrinA1-Fc (C, bottom). 
(D) Resulting displacement curve and corre-
sponding IC50 value after exposure to increas-
ing concentrations of EphrinA1-Fc. (E) In-cell 
binding using IR800-progranulin and DRAQ5 
(genomic DNA) in the absence or presence of 
LCA (100  µM). (F) Signal intensity of bound 
IR800-progranulin normalized to DRAQ5. 
(G) Immunoblotting depicting RNAi-mediated 
silencing of EphA2. (H). In-cell binding assay 
using IR800-progranulin after transfection 
of siRNA against EphA2. (I) Quantification 
of IR800-progranulin signal intensity after 
DRAQ5 normalization, as in F.  (J–M) Rep-
resentative immunoblots of phosphorylated 
MAPK in quiescent PC3 (J) and HUV ECs (K) 
or phosphorylated Akt in PC3 (L) and HUV 
ECs (M) after progranulin stimulation at the 
indicated time points. (N) Immunoblotting 
and quantification of phosphorylated Akt and 
MAPK in PC3 after combination treatment of 
progranulin with LCA, as designated. Bar, ∼1 
cm (C, E, and H). Data are representative of at 
least three independent experiments and are 
reported as the fold change ± SEM. *, P < 
0.05; **, P < 0.01; ***, P < 0.001.
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transient increase in MAPK phosphorylation (Thr202/Tyr204) 
was seen at 10 min in PC3 cells and HUV ECs (Fig. 4, J and K; 
and Fig. S3, A and B). Robust and sustained activation of Akt 
(Ser473) in PC3 cells, beginning at 10 min, was seen (Figs. 4 
L and S3 C). However, no such induction of Akt signaling was 
found in HUV ECs (Figs. 4 M and S3 D). As demonstrated in 
the Progranulin physically interacts with EphA2 section, LCA 
abrogates progranulin–EphA2 interactions at the cell surface. 
Therefore, we tested whether LCA could functionally block 
the robust activation of Akt and MAPK in PC3 cells. We found 
that LCA significantly prevented Akt and MAPK phosphory-
lation when combined with progranulin (Fig. 4 N). Moreover, 
RNAi-mediated silencing of EphA2 recapitulated the effects of 
LCA on Akt and MAPK phosphorylation, insofar as receptor 
loss prevented activation of these downstream signaling effec-
tors (Fig. S3 E). Collectively, these data posit a functional sig-
naling role mediated by progranulin–EphA2 interactions.
EphA2 is required for capillary 
morphogenesis
Progranulin induces endothelial cell migration during wound 
repair (He et al., 2003), stimulates exaggerated vessel growth 
in vivo (Toh et al., 2013), and evokes VEGF expression 
(Tangkeangsirisin and Serrero, 2004). Notably, EphA2 plays a 
key role in postnatal vascular function. Although Epha2−/− mice 
are viable with no overt developmental abnormalities, endothe-
lial cells isolated from these mice do not form capillary-like 
structures in vitro in response to EphrinA1 (Brantley-Sieders et 
al., 2004). Moreover, Epha2−/− mice display an impaired tumor 
microenvironment that is not conducive for proper tumor de-
velopment and metastatic spreading (Brantley-Sieders et al., 
2005). Additional studies have shown that EphA2 is a key an-
giogenesis receptor (Kullander and Klein, 2002) and that solu-
ble EphA2 blocks tumor angiogenesis (Brantley et al., 2002).
We sought to address the potential role of progranulin in 
in vitro angiogenesis using an RNAi approach. After efficient 
knockdown of EphA2 (>85%; Fig. 5 A), we performed in vitro 
capillary morphogenesis assays. Within 4  h, vehicle-treated 
HUV ECs formed an anastomosing network of tube-like struc-
tures (Fig.  5  B), a morphogenetic process that was markedly 
enhanced by progranulin treatment (Fig. 5 C). The formation 
of capillary-like structures in HUV ECs depleted of EphA2 
was reduced, but still active (Fig. 5 D). However, progranulin 
had no further effects on the EphA2-deficient cells (Fig. 5 E). 
Quantification of the normalized tube area from five individ-
ual experiments showed a significant enhancement of capillary 
area by progranulin in the vehicle-treated cells (P < 0.001), but 
no significant effect on the EphA2-deficient endothelial cells 
(P = 0.69; Fig.  5 F). We complemented this approach with a 
collagen type I sandwich capillary morphogenesis assay after 
EphA2 depletion in the presence of progranulin (Fig. S4, A–D). 
We obtained comparable results, insofar as silencing EphA2 
prevented progranulin-evoked capillary morphogenesis (Fig. 
S4 E). As LCA displaces progranulin from EphA2 and effec-
tively blocks signaling (Figs. 2 D and 4 N), we hypothesized 
that LCA would phenocopy the loss of EphA2. We found that 
LCA significantly abrogated progranulin-mediated capillary 
morphogenesis, matching results obtained with EphA2 knock-
down with cells on Matrigel or type I collagen (Fig. S4, F–J). 
Collectively, these results provide additional evidence for a 
functional relationship between progranulin and EphA2 in the 
process of capillary morphogenesis.
Soluble progranulin is an autocrine factor 
for GRN autoregulation
It is well established that several RTK ligands have a procliv-
ity for autoregulation (Lemmon and Schlessinger, 2010). Thus, 
we tested the ability of progranulin self-regulation of GRN 
expression in HUV ECs and PC3 cells. Progranulin evoked 
endogenous GRN expression in a dose-dependent manner in 
HUV ECs (Fig. 6 A) and PC3 cells (Fig. 6 C). Significant GRN 
Figure 5. EphA2 is required for progranulin-evoked stimulation of cap-
illary morphogenesis. (A) Immunoblotting verification of EphA2 silencing. 
(B–E) Representative capillary morphogenesis bright-field images of HUV 
ECs embedded on Matrigel, transfected with siScr or siEphA2, and chal-
lenged with progranulin (100 nM). (F) Morphometric parameter quanti-
fication for surface area of the Matrigel capillary morphogenesis assay. 
The accompanying quantification represents mean tube surface area ± 
SEM from five experiments.
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induction was achieved in both cells with as little as 12.5 nM 
of progranulin (∼1 µg/ml; Fig.  6, A and C). Addition of ex-
ogenous progranulin resulted in a time-dependent increase of 
GRN in HUV ECs (Fig. 6 B) and PC3 cells (Fig. 6 D). The ki-
netics of GRN induction differed between the two cell types. 
In HUV ECs, there was a rapid (∼1 h) and significant increase 
of GRN followed by sustained GRN abundance that was stably 
maintained for up to 6 h (Fig. 6 B). In contrast, GRN expres-
sion in PC3 cells peaked at 2 h, followed by a gradual decline 
to baseline levels (Fig. 6 D). Based on the kinetic profiles, we 
performed all subsequent experiments with HUV ECs and PC3 
cells for 6 and 2 h, respectively. To complement the autoregula-
tory functions of progranulin over the GRN locus, we evaluated 
additional genes known to be regulated (VEG FA) and not reg-
ulated (Myc; Brantley-Sieders and Chen, 2004) by EphA2. We 
found that VEG FA expression was suppressed by progranulin 
(Fig. 6 E), whereas MYC expression was unchanged (Fig. 6 F). 
We also analyzed the effect of EphrinA1-Fc on GRN expression 
and found a decrease of GRN mRNA (Fig. 6 G). Collectively, 
these data demonstrate a dynamic modulation of endogenous 
GRN levels upon stimulation with progranulin in two geneti-
cally distinct cellular models.
Progranulin requires EphA2 signaling for 
its autoregulation
As a functional coupling between progranulin and EphA2, we 
tested whether progranulin-mediated autoregulation would 
require the presence of this receptor. First, we significantly 
depleted EPHA2 using three specific siRNAs targeting vari-
ous regions of the gene in HUV ECs (Fig. 7 A) and PC3 cells 
(Fig.  7  B). Loss of EphA2 substantially abrogated the auto-
regulatory property of progranulin on GRN expression in both 
cell types (Fig. 7, C and D). This effect was in stark contrast to 
that in vehicle-treated cells (Fig. 7, C and D). Individual loss 
of EPHA2 had no adverse effect on the basal GRN, suggesting 
that progranulin must first engage EphA2 for GRN autoregula-
tion. To further corroborate these results, we used the EphA2 
inhibitor, LCA. When LCA was concurrently administered with 
progranulin, there was a near-complete block of progranulin ac-
tivity on GRN mRNA levels in both cell types (Fig. 7, E and F).
Next, we evaluated the role of MAPK and Akt activity for 
GRN autoregulation by using known inhibitors of the MAPK 
(U0129) or Akt (LY294004) signaling pathways. Inhibiting 
either MAPK or Akt signaling blunted GRN autoregulation in 
PC3 cells (Fig. 7 G). Inhibiting with LY294004 did not prevent 
GRN induction in HUV ECs (Fig.  7  H); however, U0129 did 
prevent GRN expression (Fig. 7 H). Interestingly, these results 
match the biochemical analyses of HUV ECs (Fig.  4, K and 
M) insofar as MAPK activation was robustly activated with a 
lack of Akt phosphorylation. Collectively, these results identify 
EphA2 as a pivotal signaling receptor and implicate MAPK and 
Akt as key components of the signaling apparatus needed for 
progranulin-mediated induction of GRN expression.
Sortilin is not directly involved in 
progranulin autoregulation
Sortilin has been proposed as an endocytic receptor for progran-
ulin (Hu et al., 2010). Thus, we tested whether sortilin could 
also be involved in GRN autoregulation. SORT1 knockdown 
was verified in HUV ECs (Fig. 8 A) and PC3 cells (Fig. 8 C). As 
was the case for EPHA2, stimulation with exogenous progran-
ulin did not modulate basal SORT1 (Fig. 8, A and C). Notably, 
knockdown of SORT1 evoked a threefold increase in GRN ex-
pression, comparable to levels evoked by exogenous progranu-
lin in the presence or absence of sortilin (Fig. 8, B and D).
Because silencing of sortilin leads to a significant ac-
cumulation of extracellular progranulin (Hu et al., 2010), we 
postulated that loss of sortilin would trigger accumulation of 
extracellular progranulin, which in turn would signal through 
EphA2 for GRN autoregulation. Next, a dual-RNAi approach 
was used wherein EPHA2 and SORT1 were depleted simulta-
neously in HUV ECs (Fig. 8, E and F) and PC3 cells (Fig. 8, H 
and I). Progranulin alone had no regulatory effects on EPHA2 
or SORT1 (Fig. 8, E, F, H, and I). In agreement with the results 
shown in the previous section, progranulin increased GRN ex-
pression in the presence of nontargeting siRNA (Fig. 8, G and 
J). Moreover, induction of GRN was equivalent in magnitude 
to loss of SORT1 alone (Fig. 8, G and J). Importantly, dual loss 
of EPHA2 and SORT1 ablated GRN expression compared with 
individual SORT1 silencing in HUV ECs (Fig.  8  G) and PC3 
(Fig. 8 J). Because sortilin is a high-affinity endocytic receptor 
Figure 6. Progranulin stimulates GRN expression in HUV ECs and PC3 
cells. (A and C) Dose–response of GRN in HUV ECs (A) or PC3 cells (C) to 
progranulin (6 h) at the indicated concentrations. (B and D) Time course 
of GRN expression in HUV ECs (B) or PC3 cells (D) after progranulin (50 
nM) at the indicated time points. (E and F) Analysis of VEG FA (E) and 
MYC (F) expression after progranulin treatment (50 nM, 2 h). (G) Analysis 
of GRN mRNA after EphrinA1-Fc (50 nM, 2 h). Data are the result of at 
least three independent experiments and are reported as fold change ± 
SEM. ACTB served as an internal housekeeping gene for all expression 
analyses. Statistical significance for A–D was determined via one-way 
ANO VA (*, P < 0.05; **, P < 0.01).
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for progranulin, we tested whether loss of sortilin would sub-
sequently increase progranulin binding to EphA2, resulting in 
enhanced autoregulation. We depleted sortilin (Fig.  8  K) and 
found that 60% of the IR800-labeled progranulin still bound 
to the cell surface, thereby indicating no augmented binding to 
EphA2 after sortilin knockdown (Fig.  8  L). Thus, in support 
of our hypothesis that loss of sortilin resulted in accumulated 
progranulin that is subsequently signaling via EphA2 for GRN 
autoinduction, PC3 cells were depleted of sortilin (Fig. S4 K), 
and progranulin levels in the conditioned media were measured 
via ELI SA. A standard curve was generated for progranulin 
(Fig. S4 L) and used for calculating progranulin levels. As pre-
dicted, loss of sortilin resulted in a significant accumulation of 
progranulin in the conditioned media (Fig. S4 M). This increase 
in progranulin may be sufficient for activating EphA2 for GRN 
induction after sortilin depletion.
Collectively, these data indicate that loss of EphA2 pre-
vents GRN autoinduction stemming from the single loss of 
sortilin, and that this is seemingly independent of exogenous 
progranulin. As such, this effect is presumably occurring as a 
result of compromised progranulin reuptake as coordinated by 
the dedicated endocytic functions of sortilin.
Progranulin stimulates GRN 
promoter activity
To further investigate the autoregulatory loop of progranulin, 
we generated two stably transfected PC3 cells (mass cultures) 
containing either a promoterless GFP construct (PC3GFP) or 
reporter cells (PC3GRN-GFP) expressing GFP driven by a 1.8-
kb genomic fragment of the human GRN promoter (Fig. 9 A). 
In addition, we generated stably transfected PC3 cells (mass 
cultures) harboring the same human GRN promoter driving 
the firefly luciferase gene (PC3GRN−Luc; Fig. 9 A). Progranulin 
had no effect on GFP levels in the PC3GFP cells vis-à-vis vehi-
cle-treated controls (Fig. 9 B). In contrast, progranulin evoked 
about a 12-fold increase of GFP in the PC3GRN-GFP cells, which 
was efficiently blocked by LCA (Fig. 9 B).
In support of these findings, progranulin evoked lucifer-
ase activity in PC3GRN-GFP (Fig. 9 C). Concurrent treatment with 
LCA and progranulin completely abrogated progranulin-medi-
ated luciferase activity (Fig. 9 C). Because PC3 cells synthe-
size high levels of progranulin (He and Bateman, 2003; Cenik 
et al., 2012), we tested whether GRN autoregulation would be 
influenced by endogenous progranulin. As such, GRN was si-
lenced from PC3GFP and PC3GRN-GFP cells (Fig. 9, D and E). As 
expected, progranulin increased endogenous GRN in the vehi-
cle-treated cells (Fig. 9 D). Analysis of GFP after endogenous 
progranulin depletion revealed that despite loss of cellular pro-
granulin, exogenous progranulin was sufficient for GRN-GFP 
activity (Fig. 9 E). Interestingly, loss of GRN alone had no con-
siderable effect on basal GRN-GFP (Fig. 9 E). These findings 
suggest that progranulin may not maintain basal GRN activity, 
at least in the context of the 1.8-kb promoter fragment used for 
the reporter (Fig. 9 E).
Figure 7. EphA2 is required for progranulin-mediated autoreg-
ulation of GRN. (A and C) Depletion of EPHA2 (A) and resulting 
effect on GRN (C) in HUV ECs after progranulin stimulation (6 h). 
(B and D) EphA2 silencing in PC3 cells (B) and ensuing effect 
on GRN after progranulin (2 h; D). (E and F) Pharmacological 
manipulation of HUV ECs (E) and PC3 cells (F) with LCA in com-
bination with progranulin and queried for GRN expression. (G 
and H) Evaluation of GRN expression after pretreatment (1 h) of 
PC3 cells (G) or HUV ECs (H) with the MAPK inhibitor (U0129, 
10 µM) or Akt inhibitor (LY294004, 10 µM) and stimulated with 
progranulin. Data result from at least three independent experi-
ments and are reported as fold change ± SEM. *, P < 0.05; **, 
P < 0.01; ***, P < 0.001.
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Next, we validated the concept of progranulin-evoked 
self-induction via fluorescence imaging of the reporter GFP cells. 
Exogenous progranulin had no effect on GFP when applied to 
PC3GFP cells (Fig. S5, A and B); in contrast, progranulin induced 
GFP in PC3GRN-GFP (Fig. S5, C and D). Immunoblotting for GFP 
revealed a significant increase in GFP protein levels (Fig. S5, E 
and F), further confirming the reporter data. Loss of sortilin did 
not perturb activation of the GFP reporter (Fig. S5 J), as induction 
was comparable to progranulin alone (Fig. S5 H). Furthermore, 
silencing of sortilin alone did increase reporter activity (Fig. S5 I) 
compared with control (Fig. S5 G).
Finally, endogenous progranulin was depleted, and no sig-
nificant induction after loss of progranulin alone was observed 
(Fig. S5, K and M). Stimulation of the GFP reporter with ex-
ogenous progranulin was similar in the presence (Fig. S5 L) or 
absence (Fig. S5 N) of endogenous progranulin. Collectively, 
these data reinforce the notion of GRN autoregulation and fur-
ther underscore that GRN-driven GFP expression and luciferase 
activities are dependent on competent EphA2 signaling.
Discussion
In this study, we used an unbiased screening approach to iden-
tify a cell surface RTK whose activation, as determined by 
the degree of Tyr phosphorylation, is evoked by recombinant, 
soluble progranulin. Our main hypothesis is that the signaling 
cascade evoked by progranulin is likely mediated by a classic 
RTK, insofar as canonical transduction pathways triggered by 
RTKs include the MAPK/PI3K/Akt/FAK/paxillin signaling 
apparatus. Using this platform, we discovered three members 
of the Eph family of RTKs (EphA2, EphA4, and EphB2) and 
EGFR that were rapidly activated by progranulin. We focused 
our studies on EphA2 because this receptor gave the most ro-
bust Tyr phosphorylation and because it was also the first Eph 
receptor to be activated. Moreover, EphA2 seemingly plays a 
central role in receptor cross talk and mediated progranulin sig-
nal transduction with other RTKs.
Specific interactions between EphA2 and progranulin 
were validated by a multitude of complementary approaches 
such as solid-phase binding assays (Kd ∼18 nM), microscale 
thermophoresis (Kd ∼1.2 nM), pull-downs using EphA2-Fc, 
cell binding assays, and in vitro synthesized, label-free sys-
tems. Progranulin binding to EphA2 was further confirmed via 
affinity chromatography, in which progranulin was vectorially 
bound via a C-terminal His6-tag to Ni-NTA beads.
Indeed, the binding affinity between progranulin and 
EphA2 is similar to the reported interaction of progranulin and 
sortilin (∼15.4 nM; Hu et al., 2010). Intriguingly, using Eph-
rinA1 as a positive control for EphA2 binding, we found a much 
tighter interaction (Kd ∼17 nM) for EphrinA1/EphA2 compared 
with previously published studies (e.g., Kd ∼330 nM for the 
monomer and Kd ∼144 nM for dimeric EphrinA1; Ferluga et 
al., 2013). The apparent differences may reside with the meth-
odology used (sandwich ELI SAs using Fc-fusion proteins ver-
sus surface plasmon resonance with data-fitting to a single site).
Cell surface binding proteins ranging between 120 and 
140 kD have been previously cross-linked to 125I-labeled pro-
granulin or granulins (Culouscou et al., 1993; Xia and Serrero, 
1998). The 1:1 cross-linking and the overall molecular mass 
are in agreement with previous studies (EphA2 is ∼120 kD). 
It is widely accepted that Eph receptors require clustered, GPI- 
anchored ligands regulating intercellular and integrated cross 
talk among multiple signaling pathways. There is now evidence 
Figure 8. EphA2, but not sortilin, allows 
GRN induction after progranulin stimulation. 
(A and B) In HUV ECs, verification of SORT1 
depletion (A) and evaluation of GRN (B). (C 
and D) Verification of SORT1 depletion in PC3 
cells (C) and GRN expression (D) after chal-
lenge with progranulin. (E–G) Dual silencing 
and confirmation of EPHA2 loss (E) and SORT1 
loss (F) and subsequent evaluation of dual 
knockdown on GRN (G) in HUV ECs. (H–J) 
Identical experiment performed in PC3 cells. 
For E–J, siScr was transfected and stimulated 
with progranulin (50 nM). For dual silencing, 
siRNA for EPHA2 and SORT1 were mixed and 
transfected in tandem, without exogenous 
progranulin. (K and L) Verification of sortilin 
depletion (K) and quantification of in-cell bind-
ing assay using IR800-labeled progranulin in 
PC3 cells (L). Data are the result of at least four 
independent experiments and are reported as 
fold change ± SEM. Statistical analyses for 
conditions with three or more groups, one-way 
ANO VA (**, P < 0.01; ***, P < 0.001).
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that secreted EphrinA1 can activate its cognate receptor EphA2 
as a soluble monomer (Wykosky et al., 2008; Wykosky and 
Debinski, 2008). In further support of our previous studies, 
large multimolecular complexes were noted, suggesting the for-
mation of multimeric aggregates of EphA2, and perhaps other 
Eph receptors excluding TNFR1 and sortilin, upon engagement 
with soluble progranulin. Moreover, in both cases, there were 
two binding sites with high and low affinity, ranging between 
43–200 pM and 4–10 nM, respectively (Culouscou et al., 1993; 
Xia and Serrero, 1998). Notably, in both cell-free and live cell 
experiments, EphA2 bound to progranulin could be competed 
by EphrinA1-Fc and LCA. Moreover, loss of EphA2 resulted 
in a significant loss of progranulin binding at the cell surface.
We believe that the widely accepted notion that Eph re-
ceptors require cell surface Ephrin ligands to mediate either 
forward or reverse signaling has driven researchers away from 
focusing on this class of RTKs. In retrospect, the relationship 
between progranulin, a factor that regulates neurite outgrowth 
and enhances neuronal survival (Van Damme et al., 2008), 
and Eph receptors, which are highly expressed in the central 
nervous system and are often neurotrophic, should have been 
considered. Notably, in contrast to the large number of Eph re-
ceptors (n = 14) and Ephrin ligands (n = 8) in mammals, Dro-
sophila melanogaster and Caenorhabditis elegans have only 
one Eph receptor and comparatively fewer Ephrins, suggesting 
that the remarkable expansion of Eph receptors during evolu-
tion could be linked to brain expansion in more complex mam-
malian systems (Yamaguchi and Pasquale, 2004). Moreover, 
the expression of most Eph RTKs is restricted to the central ner-
vous system, where they regulate axonal guidance by mediating 
repulsive signals for improper synaptic connections (Yamagu-
chi and Pasquale, 2004). Deleting EphA2 disrupts proper align-
ment of equatorial epithelial cells and prevents constriction of 
the elongating epithelium within the lens fulcrum during lens 
morphogenesis (Cheng et al., 2013) and coincident with the 
development of cortical cataracts (Jun et al., 2009). Mutations 
common in congenital cataracts arise within the intracellular 
SAM domain of EphA2 and result in impaired receptor stability 
and aberrant localization (Park et al., 2012; Dave et al., 2016).
EphA2 has been implicated in promoting many types of 
cancer, including melanomas (Margaryan et al., 2009; Parri 
et al., 2009), castration-resistant prostate carcinomas (Taddei 
et al., 2009), and mammary and pancreatic adenocarcinomas 
(Duxbury et al., 2004; Brantley-Sieders et al., 2008; Wykosky 
and Debinski, 2008; Kessenbrock et al., 2015). EphA2 has 
also been implicated in promoting tumor neovascularization 
(Ogawa et al., 2000; Chan and Sukhatme, 2009) and vascular 
mimicry (Hess et al., 2001). Moreover, EphA2 coordinates 
CD8+ T cell tumor infiltration for increased tumorigenicity and 
altered tumor immunogenicity (Wesa et al., 2008). Conversely, 
Epha2−/− mice exhibit less tumorigenicity in the ApcMin/+ sys-
tem (Bogan et al., 2009) and are characterized by a compro-
mised tumor microenvironment (Brantley-Sieders et al., 2005) 
with impaired metastatic potential and angiogenesis (Brant-
ley-Sieders et al., 2005). It is likely that the high-affinity in-
teractions between progranulin and EphA2, with downstream 
activation of the MAPK/Akt cascade, JNK signaling (Song et 
al., 2014), and β-catenin (Huang et al., 2014), may underscore 
the mechanism by which progranulin mediates malignant trans-
formation for a variety of solid tumors (He and Bateman, 2003; 
Monami et al., 2006, 2009; Lovat et al., 2009; Tanimoto et al., 
2015). Moreover, the EphA2/Akt and EphA2/MAPK signaling 
pathways are sensitive to LCA, an inhibitor that competes for 
progranulin binding with the EphA2 ectodomain that is further 
mirrored by EphA2 depletion.
In a manner analogous to the tumor cell expression of 
progranulin, soluble EphrinA1 is coexpressed with EphA2 and 
is secreted, presumably as an autocrine and/or paracrine me-
diator, during tumorigenesis and angiogenesis (Ogawa et al., 
2000; Wykosky and Debinski, 2008; Wykosky et al., 2008). 
Intriguingly, monomeric EphrinA1 exhibits anti-oncogenic 
properties via engagement of EphA2 via the G-H loop, a re-
gion of EphrinA1 critical for this potentially therapeutic prop-
erty (Lema Tomé et al., 2012; Kessenbrock et al., 2015). The 
interplay among the regulatory properties of the EphrinA1/
progranulin/EphA2 signaling system appear intricate and most 
likely cell type dependent.
In the present work, we have identified a previously un-
known autocrine feedback mechanism wherein exogenously 
administered progranulin is sufficient for increasing its own ex-
pression. Stimulation of the GRN locus upon additional progran-
ulin requires the presence of EphA2 and physical interaction 
Figure 9. Progranulin stimulates a GRN-GFP reporter via EphA2. (A) 
Schematic of the GFP reporter constructs of empty GFP (top), GRN-GFP 
(middle), and GRN-Luc (bottom). L, linker region of the pGL3 backbone. (B) 
Quantification of GFP from PC3GFP or the active reporter PC3GRN-GFP cells 
after progranulin. (C) PC3 cells were transiently transfected with GRN-Luc 
and assayed for luciferase activity. Modulation of GRN promoter activity 
was evaluated after incubation with progranulin with or without LCA. Data 
are shown as mean ± SEM of three independent experiments; n = 6 for 
each condition. (D and E) Quantification of GRN and GFP levels after de-
pletion of endogenous progranulin from the PC3 reporter cell lines. Data 
reported as mean ± SEM and represent at least three independent experi-
ments. **, P < 0.01; ***, P < 0.001.
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between progranulin and EphA2. As of yet, the region of pro-
granulin and/or the granulin responsible for autoinduction and 
EphA2 engagement remain unknown. It is known that granulin 
E, the most C-terminal granulin, is necessary for sortilin binding 
(Hu et al., 2010). As such, a similar requirement may be needed 
for progranulin/EphA2 and subsequent downstream activities.
Silencing or pharmacological inhibition of EphA2 signifi-
cantly prevents progranulin-mediated autoregulation. The role 
of sortilin in progranulin-mediated GRN induction appears indi-
rect, as SORT1 loss is sufficient for GRN expression. This con-
cept aligns with previous findings that focused on the depletion 
of sortilin from the neuronal compartment (Hu et al., 2010), and 
from prostate cancer cells (Tanimoto et al., 2015). The genetic 
ablation of sortilin induces a twofold increase in extracellular 
progranulin levels (Hu et al., 2010); our findings reveal a similar 
induction of endogenous GRN expression upon sortilin loss that 
is wholly abrogated after the simultaneous silencing of SORT1 
and EPHA2. A genome-wide association study has identified 
the single nucleotide polymorphism rs646776 as a key regulator 
of circulating progranulin (Carrasquillo et al., 2010). Intrigu-
ingly, this single nucleotide polymorphism maps in close prox-
imity to the SORT1 locus (Carrasquillo et al., 2010).
In the present study, we validated our biochemical data 
with functional reporter assays (GRN-Luc, GRN-GFP) and 
found a similar transcriptional induction of GRN mRNA with 
a concurrent requirement for EphA2. Importantly, depletion of 
endogenous progranulin does not alter the ability of exogenous 
progranulin in promoting GRN-GFP promoter activity, under-
scoring the non–cell-autonomous function of progranulin-me-
diated GRN induction. Interestingly, endogenously synthesized 
progranulin is not sufficient to stimulate basal reporter activity 
above control conditions.
In conclusion, the discovery of a novel functional recep-
tor for progranulin and its feedback autoregulatory loop may 
hold therapeutic promise and may provide the cornerstone for 
understanding progranulin pathobiology. For example, progran-
ulin-mediated GRN induction could be blocked with specific 
antibodies directed to the receptor itself or with small molecules 
blocking EphA2 tyrosine kinase activity (Noberini et al., 2008). 
Given that progranulin is a crucial neurotrophic factor (Van 
Damme et al., 2008), and given the epidemiological and genetic 
evidence that reduced levels of progranulin are causatively asso-
ciated with frontotemporal dementia (Baker et al., 2006; Cruts 
et al., 2006; Cruts and Van Broeckhoven, 2008; Ghidoni et al., 
2008), abnormal EphA2 activity or loss of progranulin autoin-
duction could be involved in the pathogenesis of neurodegen-
erative diseases. Moreover, the role of EphA2 in tumorigenesis 
parallels that of progranulin and may represent a key mechanism 
for progranulin- and EphA2-mediated tumorigenic growth and 
progression. Thus, any pharmacological treatment that would 
differentially modulate progranulin levels and EphA2 tyrosine 
kinase activity could be beneficial for a broad spectrum of pa-
tients suffering from progranulin-related diseases.
Materials and methods
Cells and materials
HUV ECs were obtained from Lifeline Cell Technology, grown in 
basal medium supplemented with the VascuLife EnGS LifeFactors 
kit (Lifeline Cell Technology), and used within the first five passages. 
T24 urothelial and PC3 prostate carcinoma cells were obtained from 
ATCC and maintained in Ham’s F12K-1X medium or DMEM (Corn-
ing) supplemented with 5% FBS. Dulbecco’s PBS (DPBS) was also 
purchased from Corning. Stably expressing PC3 cells were maintained 
in 200 µg/ml Hygromycin B (Thermo Fisher Scientific) supplemented 
in Ham’s F12K-1X medium. Primary antibodies for MAPK, Akt, 
phosphorylated MAPK and Akt, GFP, TNFR1, and GAP DH were pur-
chased from Cell Signaling Technology. Anti-sortilin and mouse an-
ti-phosphoEphA2/3/4 antibodies were purchased from Abcam. Primary 
antibodies for EphA2 are enumerated as follows: rabbit anti-EphA2 
(C-20) and mouse anti-EGRF were purchased from Santa Cruz Bio-
technology, Inc.; rabbit anti-EphA2 and mouse anti-EphA2 (8B6) from 
Cell Signaling Technology; and mouse anti-EphA2 (clone D7) from 
EMD Millipore and as published previously (Yang et al., 2011), as 
was the mouse anti-phosphotyrosine clone 4G10. Mouse anti-mouse 
anti-EphB2 was from Invitrogen. Mouse anti-phosphotyrosine PY20 
was obtained from EMD Millipore. HRP-conjugated goat anti–rabbit 
and donkey anti–mouse secondary antibodies were obtained from 
EMD Millipore. SuperSignal West Pico Enhanced Chemiluminescence 
substrate and mouse anti-EphA4 were purchased from Thermo Fisher 
Scientific. Doxazosin, LCA, and rabbit anti-progranulin (C terminus) 
were purchased from Sigma-Aldrich.
Expression and purification of human recombinant progranulin
A pCEP-Pu vector bearing the sequence of the BM40 signal peptide 
and full-length human progranulin was electroporated into 0.5 × 106 
HEK293-EBNA. Mass cultures were selected in media containing 250 
µg/ml G418 and 2 µg/ml puromycin. Serum-free conditioned medium 
was concentrated in a dialysis bag with polyethylene glycol, dialyzed, 
and purified on Ni-NTA resin eluted with 500 mM imidazole. In all pu-
rification steps, we used PMSF (2 mM) and N-ethylmaleimide (2 mM) 
as protease inhibitors. Typically, ∼1 mg of progranulin was purified 
from 200 ml of conditioned media. Our progranulin preparations were 
verified by colloidal Coomassie blue (EZ Blue Gel Staining Reagent; 
Sigma-Aldrich), which can detect as little as 5 ng of protein, and thus 
99.7% pure (Fig. S1 A). We did not detect any copurifying contami-
nants with this method. Throughout the study, progranulin was used at 
50 nM (4 µg/ml), unless otherwise noted.
Phospho-RTK arrays
Phospho-RTK antibody array membranes (R&D Systems) were in-
cubated with cell lysates and processed per the manufacturer's pro-
tocol using a phospho-Tyr–specific antibody. In brief, ∼3 × 107 T24 
cells were serum-starved overnight and treated with progranulin (240 
nM) for 10 min. After incubation, cells were washed with ice-cold 
DPBS and lysed with a buffer containing 1% NP-40, 20  mM Tris-
HCl, pH 8.0, 137  mM NaCl, 10% glycerol, 2  mM EDTA, 1  mM 
Na3VO4, and aprotinin/leupeptin (10 µg/ml each) for 30 min. A 
protein assay (Bio-Rad Laboratories) was performed before incu-
bating the RTK membranes.
Solid-phase binding assays
ELI SAs were performed according to a standard protocol. Pro-
granulin or EphA2-Fc (Sigma-Aldrich; 100 ng/well) was allowed 
to adhere to the wells overnight at RT in the presence of carbonate 
buffer, pH 9.6. Plates were washed with PBS and incubated for 2 h 
with serial dilutions of EphA2-Fc or progranulin. After incubation, 
plates were extensively washed with PBS, blocked with 1% BSA/
PBS, and incubated for 1  h with an antibody raised against EphA2 
(H-77; Santa Cruz Biotechnologies, Inc.) or progranulin (Abcam). 
An anti-rabbit HRP-conjugated secondary antibody (EMD Millipore) 
was incubated for 1 h. Signal was developed using Sigma-Fast tab-
lets and read at 450 nm OD.
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Binding of progranulin or EphrinA1 to EphA2 via  
microscale thermophoresis
Protein–protein interactions between purified progranulin and 
EphA2-Fc or EphrinA1-Fc and EphA2-Fc (R&D Systems) were 
evaluated by changes in the thermophoretic mobility (Wienken et al., 
2010) of progranulin or EphrinA1 labeled with the fluorophore NT-
647 (Monolith NT Protein Labeling kit; NanoTemper Technologies). 
A titration series of EphA2-Fc (1 µM to 0.4 nM) was used, whereas 
the concentrations of NT-647–labeled progranulin or EphrinA1-Fc 
remained constant (20 nM). Labeled progranulin (20 nM) with unla-
beled BSA served as a negative control. The microscale thermopho-
retic assay was performed and quantified as previously described 
(Merline et al., 2011).
Immunoprecipitation
Approximately 8 × 106 HUV ECs were serum-starved for 1 h, incubated 
with progranulin for 30 min, and lysed in 1% NP-40 buffer. Lysates 
were cleared at 14,000 rpm for 10 min and subjected to immunopre-
cipitation with an anti–C terminus EphA2 antibody (C-20, Santa Cruz 
Biotechnologies, Inc.). Samples were separated via 8% SDS-PAGE 
and immunoblotted for EphA2 and phospho-Tyr. Protein A–conjugated 
Sepharose beads (GE Healthcare) were rotated with 12 µg EphA2-Fc 
chimera (Sigma-Aldrich) for 8 h at 4°C. The beads were pelleted by 
centrifugation, resuspended, and allowed to rotate for 16 h at 4°C with 
a nonspecific mouse IgG that served to block any unbound protein 
A. The beads were pelleted again; resuspended in DMEM; and split 
into aliquots, each receiving 100 nM progranulin, increasing amounts 
of mouse EphrinA1, or both; and incubated at 37°C for 2 h with oc-
casional tapping. The beads were spun down, washed with PBS three 
times, resuspended in reducing buffer, and heat-denatured at 100°C. The 
samples were analyzed on an 8% SDS-PAGE gel. After transfer, blots 
were blocked with 5% BSA in Tris-buffered saline for 1 h and probed 
overnight with mouse monoclonal anti His5 (5-Prime) and rabbit poly-
clonal anti-progranulin (EMD Millipore). The blots were washed four 
times in Tris-buffered saline/0.1% Tween-20 for 10 min before incu-
bation with IR800-labeled goat anti-rabbit and IR680-labeled goat 
anti-mouse secondary antibodies (LI-COR Biosciences). Images were 
obtained using Odyssey Imager V3.0 (LI-COR Biosciences).
In vitro transcription/translation of full-length EphA2
Native, full-length Myc-tagged EphA2 was synthesized using the TnT 
Quick Coupled Transcription/Translation System (L1170; Promega) 
with a TrueORF Gold expression plasmid purchased from Origene ac-
cording to the manufacturer’s instructions. In brief, 1 µg of purified 
EPHA2 plasmid was combined with TnT quick master mix and 1 mM 
methionine in the presence of nuclease-free water. After gentle mix-
ing, the reaction was allowed to dwell at 30°C for 90 min, and the 
products of the in vitro reaction were verified by SDS-PAGE. After 
identification of the correct product, the lysates were used for immu-
noprecipitation in the presence of His6-tagged human recombinant pro-
granulin as described earlier.
Capillary morphogenesis assays
Four-well slides (Thermo Fisher Scientific) were coated with ∼200 µl 
of Matrigel (BD) containing VEG FA (20 ng/ml) and heparin (1 µg/ml) 
in the presence or absence of progranulin (100 nM). The slides were 
left in the incubator at 37°C for 30 min to let the Matrigel form a ho-
mogeneous solid layer. Approximately 104 HUV ECs were then seeded 
in each well on top of the Matrigel in medium supplemented with VEG 
FA/heparin as described earlier, with or without progranulin. After tran-
sient siRNA transfection, live cell images of the tubes were acquired 
using a DMIL LED microscope (Leica Biosystems) equipped with a 
D-LUX3 camera (Leica Biosystems) and processed for further anal-
ysis. All data were analyzed with Systat Software in SigmaPlot 12.0.
Preparation of IR800–progranulin and in-cell binding assays
Purified progranulin was labeled with the IR800 dye via the IRDye 
800CW labeling kit (LI-COR Biosciences) according to the manufac-
turer’s instructions. In brief, progranulin was mixed with the dye in 
a molar ratio of 1:1 and kept for 2 h at RT while protecting the vial 
from light with aluminum foil. Chemically, IRDye 800CW dye bears 
a reactive NHS ester group that couples to aliphatic amines, especially 
those found in lysine residues that form stable conjugates with the puri-
fied protein. The free, unconjugated dye was removed from the labeled 
progranulin by using 0.5-ml Pierce Zeba desalting spin columns. For 
the in-cell binding assays, confluent PC3 cells were incubated with 
IR800-progranulin in 0.1% BSA/DMEM in the presence or absence 
of LCA or after transient siRNA transfection for 1 h, covered, on ice. 
The cells were washed extensively, fixed in 10% formaldehyde, and 
scanned with the Odyssey Image system at 800 nm. The cells were 
washed again and incubated with the far-red fluorescent genomic DNA 
dye, DRAQ5 (1:10,000; BioStatus) in 0.1% BSA/PBS. After three 
more washes with PBS, the cells were scanned at 700 nM, and these 
values were used to normalize the IR-800 signal intensity data.
Transient RNAi-mediated silencing
We transiently transfected both HUV ECs and PC3 cells using Lipo-
fectamine RNAiMAX (Thermo Fisher Scientific) mixed with a cock-
tail of three different and validated siRNA duplexes (e.g., sense and 
antisense) directed against different regions of Homo sapiens EPHA2, 
SORT1, or GRN mRNAs (sc-29304, sc-42119, and sc-39261, respec-
tively; Santa Cruz Biotechnologies, Inc.). Sequences for the targeting 
siRNA oligos used can be found in Table S1. Medium was changed 
24 h post-transfection, and biological assays were performed at 48 h, as 
appropriate. Scramble siRNA (sc-37007; Santa Cruz Biotechnologies, 
Inc.) served as a control for all siRNA experiments presented herein. 
This protocol was used subsequent to protein (RIPA) or RNA (TRIzol 
Reagent; Thermo Fisher Scientific) isolation from samples for further 
analysis. Verification of siRNA-mediated knockdown of the target pro-
teins was determined via immunoblotting or quantitative PCR as per 
experimental condition.
Immunofluorescence, confocal laser microscopy, and Pearson’s 
coefficient of colocalization
Typically, ∼5 × 104 HUV ECs or PC3 cells were plated on 0.2% gela-
tin-coated four-well chamber slides (Nunc, Thermo Fisher Scientific) 
and grown to full confluence. Cells were treated at the indicated time 
points with progranulin or LCA (100 µM). After treatment, cells were 
rinsed twice with cold DPBS (Thermo Fisher Scientific) and fixed in 
4% (wt/vol) paraformaldehyde for 30 min. After washing, the slides 
were incubated with Alexa Fluor 488– or 564–conjugated secondary 
antibodies for 1  h at RT. Nuclei were visualized with DAPI (Vector 
Laboratories). Slides were then extensively washed and coverslips 
mounted with Vectashield (Vector Laboratories). Confocal analysis 
was performed using a 63×, 1.3 oil-immersion objective of an LSM-
780 confocal laser-scanning microscope (ZEI SS) with filters set at 
488/594 nm for dual-channel imaging. To determine colocalization of 
the two proteins, z-stack series were acquired maintaining the same 
number of slices (n = 30). All images were then analyzed in ImageJ 
and Photoshop CS6 (Adobe Systems). Line scanning plots were gen-
erated using SigmaPlot software (Systat Software). For GFP, images 
were acquired with a 63×, 1.3 oil-immersion objective installed on 
an DM5500B microscope (Leica Biosystems) with Leica Applica-
tion Suite v1.8 software.
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We calculated the weighted Pearson’s coefficient of colocaliza-
tion using the on-board colocalization function in the LSM-780 Zen 
software package. We started by establishing threshold fluorescence 
levels for each channel (excluding DAPI). The threshold represents 
the fully saturated population of pixels that each channel intrinsically 
contains. After the thresholds were determined, all images for that par-
ticular experiment were taken without changing that value. Thus, we 
recorded the percentage of pixels involved in the colocalization sepa-
rately and combined (e.g., red and green channels). The more intense 
the colocalization appeared, the higher the proportion of pixels (indi-
vidual and merged) involved in the image. The tabulated values reflect 
the mean of three independent experiments (n = 15 images per exper-
iment) and are presented as box plots. Importantly, this quantification 
was done for all colocalized pixels and does not reflect measurements 
of a specific cellular or subcellular compartment.
Affinity chromatography
Progranulin (20 µg) was bound overnight at 4°C with rotation to 200 µl 
of HisPur Ni-NTA beads (Thermo Fisher Scientific) in PBS, 0.3  M 
NaCl, and 20 mM imidazole, pH 7.4. The beads were allowed to settle 
in a chromatography column and, once the column was formed, RIPA 
buffer diluted 1:15 (vol/vol) with binding buffer was passed through 
it to equilibrate the beads. Approximately 2 × 107 PC3 cells were ex-
tracted in RIPA buffer diluted 1:15 (vol/vol) with binding buffer. After 
extensive washes, elution buffer containing PBS and 500  mM imid-
azole, pH 7.4, was added to the column, and several fractions were 
collected and subjected to electrophoresis on 10% SDS/PAGE. Proteins 
were then transferred to nitrocellulose membranes (Bio-Rad), probed 
with indicated antibodies, developed with enhanced chemilumines-
cence (Thermo Fisher Scientific), and detected using ImageQuant 
LAS-4000 (GE Healthcare).
Quantitative real-time PCR
Expression analysis by quantitative real-time PCR was performed on 
subconfluent six-well plates seeded with ∼2 × 105 HUV ECs or PC3 
cells. Cells were treated with progranulin in growth factor–supplemented 
serum (2%) Basal Endothelial Medium (LifeCell Technology), or Ham’s 
F12K-1X medium supplemented with 10% FBS, respectively. After in-
cubation, cells were lysed directly in 1 ml of TRIzol reagent to extract 
total RNA. After quantification, 1 µg of total RNA was annealed with 
oligo (dT18–20) primers (Thermo Fisher Scientific), and cDNA was syn-
thesized with the aid of SuperScript Reverse transcription II (Thermo 
Fisher Scientific). Amplicons representing target genes (GRN, SORT1, 
EPHA2, and GFP) and the endogenous housekeeping gene, ACTB, were 
amplified in quadruplicate, independent reactions using the Brilliant 
SYBR Green Master Mix II (Agilent Technologies). All samples were 
run on the Roche LightCycler 480-II Real Time PCR platform (Roche), 
and the cycle number (Ct) was recorded for each independent reaction. 
Fold change determinations were made using the comparative Ct method 
for expression analysis. ΔCt values represent gene expression levels 
normalized to ACTB for each reaction. ΔΔCt values then represent the 
experimental cDNA minus the corresponding gene levels of the calibra-
tor sample. Fold changes were calculated using the double ΔCt method 
(2−ΔΔCT) ± SEM. Data derive from three to five independent trials run in 
quadruplicate for each gene of interest.
Promoter luciferase reporter assays
PC3 cells were transiently transfected with the GRN-Luc reporter 
plasmid containing a 1.8-kb genomic fragment encompassing the 
human GRN promoter cloned upstream of firefly luciferase. Cells were 
cotransfected with the Renilla luciferase plasmid for normalization 
and to determine transfection efficiency. After 48 h, cells were treated 
individually or in combination with 50 nM progranulin or 100 µM LCA 
for 6 h. Luciferase activity was assayed using firefly luciferase assay 
kit and Renilla luciferase assay kit from Biotium. The data from three 
independent experiments were normalized on Renilla luciferase.
Quantification and statistical analysis
Immunoblots were quantified by scanning densitometry using Scion 
Image software (National Institutes of Health). Graphs were generated 
using Sigma Stat 3.10. Significance of the differences was evaluated by 
Student’s t test with significance at P < 0.05. All data presented herein 
were collected from a minimum of three independent experiments. Ex-
periments with more than three treatment groups, dose curves, or time 
courses were subjected to one-way analysis of variance (ANO VA) fol-
lowed by a Bonferroni post hoc test. Differences among the conditions 
were considered significant at two-sided P < 0.05.
Online supplemental material
Fig. S1 verifies human recombinant progranulin purity, activation of 
EphA2 receptor upon binding, dependence of EphA2 in receptor cross 
talk, and complementary binding methods. Fig. S2 reveals that exog-
enous progranulin localizes with EphA2 and promotes EphA2 phos-
phorylation in PC3 cells, triggers EphA2 internalization, and does not 
associate with TNFR1 or sortilin. Fig. S3 shows phosphorylation of 
MAPK and Akt over time and reliance on EphA2 for Akt and MAPK 
activation. Fig. S4 contains bright-field images of a type I collagen 
capillary morphogenesis assay and ensuing effects of EphA2 loss with 
quantification as well as images depicting effects of LCA on capillary 
morphogenesis with quantification. Also, loss of sortilin increases pro-
granulin levels in PC3-conditioned media. Fig. S5 illustrates that ex-
ogenous progranulin drives GRN-GFP activity downstream of EphA2. 
Table S1 shows siRNA sequences.
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